{
  "@context": "https://schema.org",
  "@type": "FinancialProduct",
  "registryType": "xrpl-rwa-asset",
  "symbol": "CELV",
  "name": "Celvionics Life Sciences",
  "network": "XRP Ledger",
  "currencyCode": "CELV",
  "issuerAccount": "rih5FQgmPACmgfEKtbKYLkdmjYztEZHBm",
  "ammAccount": "rsDk81cbYtukDN4t2Hvq2qAmMM3wo8xUzZ",
  "quoteAsset": "USD",
  "category": "Tokenized Private Equity",
  "subClass": null,
  "issuer": {
    "slug": "celvionics",
    "name": "Celvionics Life Sciences",
    "type": "Private market issuer",
    "website": "https://celvionics.com/",
    "html": "https://dexlocate.com/issuer/celvionics"
  },
  "description": "Celvionics Life Sciences is a precision immunology company developing advanced antibody therapies and immunological solutions for autoimmune, inflammatory, and rare diseases.",
  "assetThesis": "Celvionics is focused on engineering biologic therapies for complex immune-mediated conditions, where targeted antibody approaches can create differentiated treatments for patients with limited options.",
  "whatItDoes": "Celvionics develops antibody therapeutics, immune pathway science, and biologic innovation for autoimmune, inflammatory, and rare disease areas. Its work translates immunology research into therapeutic programs and precision medicine solutions.",
  "businessModel": "Celvionics develops life-sciences therapeutics through intellectual property creation, preclinical and clinical development, research partnerships, licensing opportunities, and strategic collaborations around antibody and immunology assets.",
  "structure": "CELV is a tokenized equity-linked instrument connected to Celvionics Life Sciences. The structure uses a $15,000,000 company valuation, 5% tokenized exposure, and a $750,000 tokenized allocation represented by 250,000 CELV at a $3.00 launch price.",
  "whySpecial": "Celvionics operates in a specialized area where precision immunology and antibody engineering can address diseases that are difficult to treat with broad, non-targeted approaches. The business is compelling because successful biologic programs can create defensible intellectual property, high clinical value, and partnership potential in large therapeutic markets.",
  "sectors": [
    "Precision immunology",
    "Antibody therapeutics",
    "Autoimmune disease",
    "Inflammatory disease",
    "Rare diseases"
  ],
  "highlights": [
    "Precision immunology and antibody therapeutics focus",
    "Autoimmune, inflammatory, and rare disease applications",
    "Potential for defensible biologic IP and strategic life-sciences partnerships"
  ],
  "tokenomics": {
    "valuation": 15000000,
    "tokenizedPercent": 5,
    "tokenizedValue": 750000,
    "launchPrice": 3,
    "launchSize": 250000
  },
  "links": {
    "html": "https://dexlocate.com/token/CELV",
    "json": "https://dexlocate.com/registry/assets/CELV.json",
    "website": "https://celvionics.com/",
    "issuerPage": "https://celvionics.com/",
    "disclosure": null,
    "xrpl": "https://livenet.xrpl.org/token/CELV.rih5FQgmPACmgfEKtbKYLkdmjYztEZHBm",
    "trade": "https://trensik.com/trade/xrpl:issued:CELV:rih5FQgmPACmgfEKtbKYLkdmjYztEZHBm",
    "logo": "https://celvionics.com/celv.png"
  },
  "lastRegistryUpdate": "2026-06-27"
}